Steve Davis, Acadia CEO
Acadia's prized pain drug from $52M buyout flops its first test
When Acadia Pharmaceuticals put down $52.5 million in cash to buy out CerSci Therapeutics – along with $887 million in biobucks – in 2020, CEO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
